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Cancers are frequently addicted to oncogenic missense mutant p53 (mutp53). DNAJA1, a member of heat shock protein 40 (HSP40),
also known as J-domain proteins (JDPs), plays a crucial role in the stabilization and oncogenic activity of misfolded or
conformational mutp53 by binding to and preventing mutp53 from proteasomal degradation. However, strategies to deplete
mutp53 are not well-established, and no HSP40/JDPs inhibitors are clinically available. To identify compounds that bind to DNAJA1
and induce mutp53 degradation, we performed an in silico docking study of ~10 million of compounds from the ZINC database for
the J-domain of DNAJA1. A compound 7-3 was identiﬁed, and its analogue A11 effectively reduced the levels of DNAJA1 and
conformational mutp53 with minimal effects on the levels of wild-type p53 and DNA-contact mutp53. A11 suppressed migration
and ﬁlopodia formation in a manner dependent on DNAJA1 and conformational mutp53. A mutant DNAJA1 with alanine mutations
at predicted amino acids (tyrosine 7, lysine 44, and glutamine 47) failed to bind to A11. Cells expressing the mutant DNAJA1
became insensitive to A11-mediated depletion of DNAJA1 and mutp53 as well as A11-mediated inhibition of cell migration. Thus,
A11 is the ﬁrst HSP40/JDP inhibitor that has not been previously characterized for depleting DNAJA1 and subsequently
conformational mutp53, leading to inhibition of cancer cell migration. A11 can be exploited for a novel treatment against cancers
expressing conformational mutp53.
Cell Death Discovery (2022)8:437 ; https://doi.org/10.1038/s41420-022-01229-5

INTRODUCTION
Targeting cancer-speciﬁc events is crucial for efﬁcient anticancer therapies with minimal side effects [1]. Mutations in the
tumor suppressor p53 are one of the most frequent cancerspeciﬁc events [2, 3]. Most p53 mutations are missense
mutations, resulting in loss of function (LOF) as a tumor
suppressor, as well as gain of new oncogenic activities (gain of
function: GOF), which cannot simply be explained by p53 LOF
[4, 5]. Accumulation of mutant p53 (mutp53) is central to
displaying the oncogenic GOF [6–9]. High levels of mutp53 are
frequently detected in human cancers, which is correlated with
poor outcomes [10–13], while depletion of mutp53 inhibits
malignant progression of cancer cells [14–17], suggesting the
key role of mutp53 in cancer progression and addiction of
cancers to mutp53. However, direct targeting and depletion of
missense mutp53 have been challenging [4, 5].
We recently published that misfolded or conformational mutp53
interacts with and is stabilized by DNAJA1, a member of heat
shock protein 40 (HSP40), also known as J-domain proteins
(JDPs) [17–19]. HSP40/JDPs are involved in protein translation,
folding/unfolding/refolding, and stabilization/degradation [20–22].

Clinically, DNAJA1 protein levels are increased in human head and
neck cancers, which are correlated with reduced overall survival
[18]. Knockdown of DNAJA1 triggers CHIP/STUB1 ubiquitin ligasemediated proteasomal degradation of mutp53, leading to reduced
malignant properties of cancer cells; however, knockdown of
DNAJA1 has little effect on the levels of wild-type p53 (wtp53) and
DNA-contact mutp53 [17, 18]. Thus, DNAJA1 is a conformational
mutp53-dependent tumor-promoting factor, and mutp53 can be
depleted by inhibiting DNAJA1. However, no DNAJA1- or HSP40/
JDPs-speciﬁc inhibitors are clinically available.
We hypothesize that compounds which bind to and inhibit
DNAJA1 would suppress malignant properties of cancer cells via
depletion of conformational mutp53. To test this hypothesis, we
performed an in silico docking study for the J-domain of DNAJA1
using the ZINC database with ~10 million of commercially available
compounds, which identiﬁed a compound “7-3” (3-(4-hydroxy-3methoxyphenyl)-3-(3-hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)-N-(3phenylpropyl)propanamide). Its analogue “A11” (3-(4-hydroxy-3methoxyphenyl)-3-(3-hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)-N-{3[methyl(phenyl)amino]propyl}propanamide) efﬁciently depleted
DNAJA1 and subsequently conformational mutp53 with minimal
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effects on the levels of DNA-contact mutp53 and wtp53. We
demonstrate DNAJA1- and conformational mutp53-dependent
activities of A11.
RESULTS
A virtual screen identiﬁes a compound that binds to DNAJA1
DNAJA1 binds to and stabilizes speciﬁcally conformational
mutp53, while its knockdown induces proteasomal degradation
of conformational mutp53 leading to reduced migratory potential
[18, 23–25]. Despite the potential of DNAJA1 as a therapeutic
target, no speciﬁc inhibitor for DNAJA1 or HSP40/JDPs is clinically
available. We therefore conducted an in silico docking study
using the ZINC database and selected the 32 compounds as
described in Supplementary Materials and Methods (Table 1).
These 32 compounds were tested for their abilities to deplete
DNAJA1 and conformational mutp53 in KHOS/NP (p53R156P) cells
by immunoﬂuorescence, resulting in identiﬁcation of a compound “7-3” (Fig. 1A). 7-3 showed the highest activity to reduce
both DNAJA1 and p53R156P protein levels (Fig. 1B, left). The virtual
screen also identiﬁed tyrosine 7 (Y7), lysine 44 (K44), and
glutamine 47 (Q47) as predicted amino acids crucial for binding
between 7-3 and DNAJA1 (Fig. 1B, right).
To validate the 7-3−DNAJA1 binding, we performed cellular
thermal shift assay (CETSA), which is based on the biophysical
principle of ligand-induced thermal stabilization of target
proteins in live cells [26–29]. Increased DNAJA1 levels were
detected in the supernatants of 7-3-treated p53R175H-expressing
MG63 (p53null) cells, as compared to those treated with DMSO,
indicating intracellular binding of 7-3 to DNAJA1 (Fig. 1C).
We conﬁrmed that 7-3 reduced protein levels of DNAJA1 and
conformational mutp53 in multiple cell lines, including KHOS/
NP (p53R156P), HN31 (p53C176F), and p53R175H-expressing MG63
(Fig. 1D). Furthermore, 7-3 depleted DNAJA1 and mutp53 in a
concentration- and time-dependent manner (Fig. 1E, F, Supplementary Fig. 1A-D).
Analogue screen identiﬁes A11, showing an increased activity
to deplete DNAJA1 and conformational mutp53
7-3 decreased the protein levels of both DNAJA1 and conformational mutp53, which required high centration (40 µM) and a longtime treatment period (48 h). Hence, we selected 25 analogues
based on a search of the ChemSpider (http://www.chemspider.com/)
(Table 2). These compounds were tested for their abilities to
reduce DNAJA1 and p53R156P levels in KHOS/NP cells for a shorter
treatment period (24 h) at 40 µM (Fig. 2A). A compound “A11”
showed the highest activity to reduce these proteins (Fig. 2A, B).
CETSA conﬁrmed the binding of A11 to DNAJA1 in p53R175Hexpressing MG63 cells (Fig. 2C). A11 depleted DNAJA1 and
conformational mutp53 in multiple cell lines, including KHOS/NP
(p53R156P), H2087 (p53V157F), CAL33 (p53R175H), and Huh7
(p53Y220C) cells, at lower concertation (20 µM) and a shorter
treatment period (24 h) than those used for 7-3 (Fig. 2D).
Next, we treated multiple cell lines expressing DNA-contact
mutp53 (p53R248L, p53R248Q, p53R273H, p53R280K), wtp53, or p53
null with A11 at 20 µM for 24 h. A11 showed little effect on DNAcontact mutp53 and wtp53, although it reduced DNAJA1 levels
(Fig. 2E, Supplementary Fig. 2A). Consistently, using MG63 cells
exogenously expressing p53R175H or p53R273H, we conﬁrmed that
A11 depleted p53R175H, but not p53R273H (Fig. 2F), showing the
speciﬁcity of A11 on conformational mutp53.
We also found that A11 reduced DNAJA1 protein levels at a
concentration as low as 10 µM and as early as 12 h posttreatment, while it depleted conformational mutp53 at as low
as 20 µM and as early as 24 h post-treatment, in a concentration- and treatment period-dependent manner in KHOS/NP,
CAL33, and p53R175H-expressing MG63 cells (Fig. 2G, H,
Supplementary Fig. 2B-E).

A11 induces proteasomal degradation of DNAJA1 and
subsequently reduces conformational mutp53
To examine whether depletion of DNAJA1 preceded to that of
conformational mutp53, we performed kinetic studies of DNAJA1
and mutp53 in CAL33 and KHOS/NP cells between 12 h and 24 h
following 20 µM of A11 treatment. A11 decreased DNAJA1 levels
earlier than mutp53 in both cells (Fig. 3A, Supplementary Fig. 3A).
Moreover, A11 had little effect on the protein levels of mutp53 in
DNAJA1-knockout (DNAJA1-KO) CAL33 and KHOS/NP cells
(Fig. 3B, Supplementary Fig. 3B). CETSA revealed lack of binding
of A11 to conformational mutp53 in DNAJA1-KO CAL33 cells
(Fig. 3C). A11 also failed to interfere with the DNAJA1−mutp53
binding by co-immunoprecipitation studies (Supplementary Fig.
3C). These results suggest that A11-mediated depletion of
mutp53 is dependent on the presence of DNAJA1.
Additionally, we conﬁrmed that A11 did not affect mRNA
levels of DNAJA1 and p53 in KHOS/NP and Huh7 cells
(Supplementary Fig. 3D, E). Also, A11-mediated depletion of
mutp53 was not resultant of reactivation or conformational
changes of mutp53 to wtp53 with a shorter half-life; A11 did not
increase mRNA expression of p53-downstream target genes
(Supplementary Fig. 3F, G). These observations suggest that A11
regulates protein levels of DNAJA1 and conformational mutp53
at the post-transcriptional level.
We hence determined the effects of A11 on the protein half-life
of DNAJA1 in CAL33. A11 signiﬁcantly shortened the DNAJA1
protein half-life from 11.6 to 3.2 h (Fig. 3D), suggesting reduction
of DNAJA1 protein stability by A11. Indeed, a proteasome inhibitor
substantially rescued A11-mediated reduction in the DNAJA1
protein level (Fig. 3E). Thus, A11 binds to and induces proteasomal
degradation of DNAJA1, which triggers degradation of conformational mutp53.
A11 inhibits migratory potential in a manner dependent on
DNAJA1 and conformational mutp53
Given frequent addiction of cancer cells to mutp53, we
hypothesized that cells expressing conformational mutp53 are
sensitive to A11. We determine 72h-IC50 values for A11 by MTT
assays in multiple cancer cell lines with different p53 status and
wtp53-expressing non-tumor cell lines. Cancer cells harboring
conformational mutp53 showed signiﬁcantly lower 72h-IC50
values as compared to those with other p53 status (DNAcontact, wtp53, p53 null) and non-tumor cells (Fig. 4A). To
furthermore examine the dependency of A11’s activity to
inhibit viable cell proliferation on DNAJA1 and conformational
mutp53, we used DNAJA1-knockout (JA1-KO) and mutp53knockout (p53-KO) KHOS/NP and CAL33 cells. Although JA1-KO
and p53-KO cells showed decreased sensitivity to A11 as
compared to the control cells, A11 still inhibited cell viability of
these cells (Fig. 4B, Supplementary Fig. 4A), suggesting
DNAJA1-independent activities of A11.
Since migratory potential is one of the most prominent mutp53
GOF activities, we examined the effects of A11 on suppressing
migratory potential of control, DNAJA1-KO, and p53-KO KHOS/NP
cells by transwell migration assays. A11 signiﬁcantly inhibited
migration of control cells, with little effect on migration of
DNAJA1- or mutp53-lacking cells (Fig. 4C).
DNAJA1 regulates ﬁlopodia-forming potential dependent on
mutp53, which contributes to cell migration [18]. Hence, we
performed F-actin staining using the KHOS/NP isogenic cell
lines. Expectedly, A11 failed to further inhibit ﬁlopodia
formation of cells lacking DNAJA1 or mutp53 (Fig. 4D). To
support these ﬁndings, A11 showed minimal effects on the
migratory- and ﬁlopodia-forming potential of cancer cells
expressing DNA-contact mutp53 (MDA-MB-231: p53R280K,
FaDu: p53R248L, HSC4: p53R248Q), wtp53 (SJSA1, U2OS, HCT116
p53+/+), and p53 null (MG63, HCT116 p53−/−, H1299)
(Supplementary Fig. 4B, C).
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Table 1.

Compounds tested with potential to bind to the J-domain of DNAJA1 through a docking study.

Cluster #

Rank
within
cluster

1

Structure

IUPAC

ZINC ID

Score

1

1-[(2,6-dimethyl-3-oxo-3,4-dihydro-2H-1,4benzoxazin-7-yl)sulfonyl]-N-[3-(pyrrolidin-1yl)propyl]piperidine-4-carboxamide

ZINC000032959058

−62.02

2

N-[3-(azepan-1-yl)propyl]-1-[(6-methyl-3-oxo3,4-dihydro-2H-1,4-benzoxazin-7-yl)sulfonyl]
piperidine-4-carboxamide

ZINC000032958658

−57.346

3

N-[2-(azepan-1-yl)ethyl]-1-[(2,6-dimethyl-3oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)
sulfonyl]piperidine-3-carboxamide

ZINC000106304218

−49.468

2

1

N-[(furan-2-yl)methyl]-4-[(1E)-3-oxo-3-{4-[2oxo-2-(pyrrolidin-1-yl)ethyl]piperazin-1-yl}
prop-1-en-1-yl]benzene-1-sulfonamide

ZINC000012749184

−56.415

3

1

N-[4-({[(2 R,4 S,5 R)-5-[3-(furan-2-yl)-1-methyl1H-pyrazol-5-yl]-1-azabicyclo[2.2.2]octan-2yl]methyl}sulfamoyl)phenyl]acetamide

ZINC000008635407

−52.588

4

1

3-[(4-hydroxypiperidin-1-yl)({1-[(oxolan-2-yl)
methyl]-1H-1,2,3,4-tetrazol-5-yl})methyl]-6methoxy-1,2-dihydroquinolin-2-one

ZINC000057594491

−51.514

5

1

1-[(2,4-dimethoxyphenyl)[1-(2methoxyethyl)-1H-1,2,3,4-tetrazol-5-yl]
methyl]piperidine-4-carboxamide

ZINC000004862266

−51.382

2

1-[(3,4-dimethoxyphenyl)[1-(2-phenylethyl)1H-1,2,3,4-tetrazol-5-yl]methyl]-4-(prop-2-en1-yl)piperazine

ZINC000022929948

−51.382
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Table 1.

continued

Cluster #

Rank
within
cluster

6

7

11

12

Structure

IUPAC

ZINC ID

Score

1

3-(2-ﬂuorophenyl)-6,7-dimethoxy-2-methylN-[3-(morpholin-4-yl)propyl]-1-oxo-1,2,3,4tetrahydroisoquinoline-4-carboxamide

ZINC000020114243

−49.446

1

3-(4-hydroxy-3-methoxyphenyl)-3-(3hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)-N[(1H-indol-4-yl)methyl]propanamide

ZINC000524730478

−48.607

2

3-(4-hydroxy-3-methoxyphenyl)-3-(3hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)-N-[2(1H-indol-1-yl)ethyl]propanamide

ZINC000604405644

−42.833

3

3-(4-hydroxy-3-methoxyphenyl)-3-(3hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)-N-(3phenylpropyl)propanamide

ZINC000524731832

−36.32

1

2-(benzylsulfanyl)-5-methyl-7-(3,4,5trimethoxyphenyl)-4H,7H-[1,2,4]triazolo[1,5a]pyrimidine-6-carboxamide

ZINC000004176684

−44.804

2

7-(4-ethoxy-3-methoxyphenyl)-2-(3hydroxypropyl)-5-methyl-4H,7H-[1,2,4]
triazolo[1,5-a]pyrimidine-6-carboxamide

ZINC000004177153

−41.082

3

7-(3,4-dimethoxyphenyl)-2-(3hydroxypropyl)-5-methyl-4H,7H-[1,2,4]
triazolo[1,5-a]pyrimidine-6-carboxamide

ZINC000013121860

−39.028

1

3-(4-methoxybenzenesulfonamido)-4(piperazin-1-yl)-N-[(pyridin-3-yl)methyl]
benzamide

ZINC000033033819

−43.071

Cell Death Discovery (2022)8:437

S. Nishikawa et al.

5
Table 1.

continued

Cluster #

Rank
within
cluster

IUPAC

ZINC ID

Score

2

N-cyclopentyl-4-(piperazin-1-yl)-3-(4propanamidobenzenesulfonamido)
benzamide

ZINC000033034273

−41.204

3

N-benzyl-3-(3methoxybenzenesulfonamido)-N-methyl-4(piperazin-1-yl)benzamide

ZINC000033033923

−39.444

13

1

1-{2-[3-(2,5-dimethylphenyl)-5-(4ethoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl]2-oxoethyl}piperidine-4-carboxamide

ZINC000036342583

−42.952

14

1

ethyl 1-[8-(benzenesulfonyl)-2H,3H-[1,4]
dioxino[2,3-g]quinolin-9-yl]piperidine-4carboxylate

ZINC000020381010

−42.263

15

1

3-[(3’aS,6’aR)-5-ethyl-2,4’,6’-trioxo-5’-(2phenylethyl)-1,2,3’,3’a,4’,5’,6’,6’a-octahydro2’H-spiro[indole-3,1’-pyrrolo[3,4-c]pyrrol]-3’yl]propanamide

ZINC000015969843

−42.242

2

3-[(3’aS,6’aR)-5-chloro-2,4’,6’-trioxo-5’-(2phenylethyl)-1,2,3’,3’a,4’,5’,6’,6’a-octahydro2’H-spiro[indole-3,1’-pyrrolo[3,4-c]pyrrol]-3’yl]propanamide

ZINC000015969095

−41.049

3

3-[(3’aS,6’aR)-5,7-dimethyl-2,4’,6’-trioxo-5’-(2phenylethyl)-1,2,3’,3’a,4’,5’,6’,6’a-octahydro2’H-spiro[indole-3,1’-pyrrolo[3,4-c]pyrrol]-3’yl]propanamide

ZINC000015969934

−37.396

1

3-(2-methoxyethyl)-N-[2-(morpholin-4-yl)
ethyl]-2,4-dioxo-1,2,3,4tetrahydroquinazoline-7-carboxamide

ZINC000020117031

−41.207

18

Structure

Cell Death Discovery (2022)8:437

S. Nishikawa et al.

6
Table 1.

continued

Cluster #

Rank
within
cluster

19

IUPAC

ZINC ID

Score

2

1-[3-(diethylamino)propyl]-4-(2,3-dihydro1,4-benzodioxine-6-carbonyl)-3-hydroxy-5(3-hydroxyphenyl)-2,5-dihydro-1H-pyrrol-2one

ZINC000020328954

−38.392

3

1-[3-(dimethylamino)propyl]-3-hydroxy-5-(4hydroxy-3-methoxyphenyl)-4-(4-methoxy-2methylbenzoyl)-2,5-dihydro-1H-pyrrol-2-one

ZINC000017194559

−38.008

1

3-(4-chlorophenyl)-N-[2-(3,4dihydroxyphenyl)ethyl]-3-{2-hydroxy-4-oxo4H-pyrido[1,2-a]pyrimidin-3-yl}propanamide

ZINC000096231695

−39.604

2

3-(4-chlorophenyl)-N-[2-(3,4dihydroxyphenyl)ethyl]-3-{4-hydroxy-2-oxo2H-pyrido[1,2-a]pyrimidin-3-yl}propanamide

ZINC000206246138

−38.735

22

1

N-[1-(4-benzylpiperazin-1-yl)-3-methyl-1oxobutan-2-yl]-2-oxo-2,3,4,5-tetrahydro-1H1-benzazepine-7-sulfonamide

ZINC000020981310

−38.296

23

1

6-[3-(ethoxycarbonyl)piperidin-1-yl]-5-[4(propan-2-yl)benzenesulfonamido]pyridine3-carboxylic acid

ZINC000064843663

−37.823

28

1

2-[5-(hydroxymethyl)-1H-indol-3-yl]-2-(4-{2[(2-oxo-2H-chromen-4-yl)amino]ethyl}
piperazin-1-yl)acetic acid

ZINC000031810008

−36.622

29

1

3-(3-hydroxy-4-methoxyphenyl)-3-(4hydroxy-6-methyl-2-oxo-2H-pyran-3-yl)-N-(3methoxyphenyl)propanamide

ZINC000253471635

−36.223

21

Structure
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Fig. 1 A virtual screen identiﬁes a compound that binds to DNAJA1. A Immunoﬂuorescence for p53, DNAJA1, and DAPI, using KHOS/NP
(p53R156P) cells treated with 7-3 (40 µM, 48 h). Scale bar: 50 µm. B Summary of relative immunoﬂuorescence intensities of p53 and DNAJA1,
using KHOS/NP cells treated with top 32 compounds (40 µM, 48 h, left). Chemical structure of 7-3 and images from molecular docking studies
(right), showing binding of 7-3 with the DNAJA1 J-domain at Y7 (cyan), K44 (magenta), and Q47 (orange). C CETSA for DNAJA1 and Vinculin
using MG63-p53R175H cells treated with DMSO (D) or 7-3 (100 µM, 4 h) with a quantitative graph. Mean ± SEM (n = 4). *p < 0.05; two-way
ANOVA. D Western blotting for indicated proteins using KHOS/NP, HN31 (p53C176F), and MG63-p53R175H cells treated with D or 7-3 (40 µM,
48 h). E, F Western blotting or immunoﬂuorescence for indicated proteins using KHOS/NP cells treated with different concentrations of D or
7-3 for 48 h (E) and at 40 µM of D or 7-3 for 24–72 h (F). Scale bar: 50 µm.
Cell Death Discovery (2022)8:437
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Table 2.

Analogues of 7-3 tested.

Compound name

Structure

IUPAC

7-5

N-(1,1-dioxo-1λ6-thiolan-3-yl)-3-(3-hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)-3-(4methoxyphenyl)propanamide

7-6

N-[2-(dimethylamino)-2-(furan-2-yl)ethyl]-3-(4-hydroxy-3-methoxyphenyl)-3-(3hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)propanamide

7-7

N-[3-(1H-1,3-benzodiazol-2-yl)propyl]-3-(3-hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)3-(4-methoxyphenyl)propanamide

7-8

N-[3-(furan-2-yl)propyl]-3-(4-hydroxy-3-methoxyphenyl)-3-(3-hydroxy-6-methyl-4oxo-4H-pyran-2-yl)propanamide

7-9

N-{[4-(dimethylamino)phenyl]methyl}-3-(4-hydroxy-3-methoxyphenyl)-3-(3hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)propanamide

7-10

3-(4-hydroxy-3-methoxyphenyl)-3-(3-hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)-N[(1H-indol-4-yl)methyl]propanamide

A1

3-(4-hydroxy-3-methoxyphenyl)-3-(3-hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)-N-(2phenoxyethyl)propanamide
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Table 2.

continued

Compound name

Structure

IUPAC

A2

N-[(1 S)-1-(1H-1,3-benzodiazol-2-yl)ethyl]-3-(4-hydroxy-3-methoxyphenyl)-3-(3hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)propanamide

A3

N-[3-(1H-1,3-benzodiazol-2-yl)propyl]-3-(4-hydroxy-3-methoxyphenyl)-3-(3hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)propanamide

A4

3-(4-hydroxy-3-methoxyphenyl)-3-(3-hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)-N-[3(5-methoxy-1H-indol-1-yl)propyl]propanamide

A5

3-(4-hydroxy-3-methoxyphenyl)-3-(3-hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)-N-(2{imidazo[1,2-a]pyridin-2-yl}ethyl)propanamide

A6

3-(4-hydroxy-3-methoxyphenyl)-3-(3-hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)-N-(3{[1,2,4]triazolo[4,3-a]pyridin-3-yl}propyl)propanamide

A7

3-(4-hydroxy-3-methoxyphenyl)-3-(3-hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)-N-{3oxo-3-[2-(pyridin-3-yl)piperidin-1-yl]propyl}propanamide

A8

3-(4-hydroxy-3-methoxyphenyl)-3-(3-hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)-N-(2{[(1 S,9 S)-6-oxo-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-11-yl]sulfonyl}ethyl)
propanamide
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Table 2.

continued

Compound name

Structure

IUPAC

A9

N-(3,3-diphenylpropyl)-3-(4-hydroxy-3-methoxyphenyl)-3-(3-hydroxy-6-methyl-4oxo-4H-pyran-2-yl)propanamide

A10

N-(3,3-diphenylpropyl)-3-(4-hydroxy-3-methoxyphenyl)-3-(3-hydroxy-6-methyl-4oxo-4H-pyran-2-yl)propanamide

A11

3-(4-hydroxy-3-methoxyphenyl)-3-(3-hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)-N-{3[methyl(phenyl)amino]propyl}propanamide

A12

3-(3-hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)-3-(4-methoxyphenyl)-N-[2-oxo-2(1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]propanamide

B1

3-(4-hydroxy-3-methoxyphenyl)-3-(3-hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)-N-{2[2-(pyridin-3-yl)-1,3-thiazol-4-yl]ethyl}propanamide

B2

3-(4-hydroxy-3-methoxyphenyl)-3-(3-hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)-N-{2[(pyridin-2-yl)carbamoyl]ethyl}propanamide

B3

3-(4-hydroxy-3-methoxyphenyl)-3-(3-hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)-N-{2[3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl]ethyl}propanamide
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Table 2.

continued

Compound name

Structure

IUPAC

B4

(2 S)-N-[(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)methyl]-2-[3-(4hydroxy-3-methoxyphenyl)-3-(3-hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)
propanamido]propanamide

B5

N-[(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)methyl]-3-[3-(4hydroxy-3-methoxyphenyl)-3-(3-hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)
propanamido]propanamide

B6

3-(4-hydroxy-3-methoxyphenyl)-3-(3-hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)-N{[(pyridin-2-yl)carbamoyl]methyl}propanamide

C1

4-{2-[3-(4-hydroxy-3-methoxyphenyl)-3-(3-hydroxy-6-methyl-4-oxo-4H-pyran-2-yl)
propanamido]acetamido}benzamide

Activation of Cdc42 and Rac1 is crucial for enhancing ﬁlopodia
formation [18]. Indeed, A11 reduced active forms of Cdc42 and
Rac1 in KHOS/NP cells (Fig. 4E). Together, the effects of A11 on
inhibiting ﬁlopodia formation and migration are dependent on
DNAJA1 and conformational mutp53.
A11 decreases protein levels of other HSP40/JDP members
A11 appears to have both DNAJA1-dependent (migratory
potential) and -independent (viable proliferation) activities. Considering the well-conserved J-domains among HSP40/JDPs, we
tested the hypothesis that A11 could bind to and reduce protein
levels of other HSP40/JDPs. We tested multiple HSP40/JDP
members, including DNAJA1, DNAJA2, DNAJA3, DNAJA4, DNAJB1,
DNAJB2, DNAJB6, DNAJB12, DNAJC6, DNAJC7, DNAJC10, and
DNAJC15. In both KHOS/NP and CAL33 cells, A11 consistently
depleted DNAJA1, DNAJA3, and DNAJB6, while it failed to reduce
levels of DNAJC6, DNAJC10, and DNAJC15 (Fig. 5A, B, Supplementary Fig. 5A). Other HSP40/JDP members showed varying
degrees of response to A11.
To exclude the possibility that reduction in DNAJA3 and
DNAJB6 levels could be secondary to depletion of DNAJA1 or
mutp53, we compared protein levels of DNAJA3 and DNAJB6, as
well as DNAJC6 and DNAJC10 as negative controls, among control,
Cell Death Discovery (2022)8:437

DNAJA1-KO, and p53-KO CAL33 cells. There was no difference in
these protein levels among these subcell lines (Supplementary Fig.
5B), suggesting direct effects of A11 on these protein levels.
Indeed, CETSA revealed that A11 bound to DNAJB6, but not
DNAJC6, in MG63-p53R175H cells (Fig. 5C).
Next, we examined possible correlation between A11 response
and amino acid sequences of J-domains among HSP40/JDP
members examined above (Fig. 5D). Good responders (DNAJA1,
DNAJA3, DNAJB6) had three predicted amino acids (Y7, K44, Q47)
key for the 7-3−DNAJA1 binding (Fig. 1B), while little or no
responders (DNAJC6, DNAJC10, DNAJC15) lacked all these three
residues (Fig. 5D). These results may suggest critical roles of these
three residues in A11’s binding to HSP40/JDPs and subsequent
depletion of the binding targets.
A triple mutant DNAJA1 with alanine mutations at Y7, K44,
and Q47 does not respond to A11
To examine the signiﬁcance of Y7, K44, and Q47 residues on A11mediated cellular phenotypes, we generated a triple mutant
DNAJA1 with alanine substitution (Y7A/K44A/Q47A: mutDNAJA1),
followed by re-introduction of wild-type DNAJA1 (wtDNAJA1) or
mutDNAJA1 into DNAJA1-KO CAL33 cells. First, we compared
protein levels of mutp53 (p53R175H) and DNAJA1 and their
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response to A11 between wtDNAJA1- and mutDNAJA1-expressing
DNAJA1-KO CAL33 cells (Fig. 6A, B). The levels of mutp53 in
DNAJA1-KO cells were restored by wtDNAJA1 and mutDNAJA1.
A11 efﬁciently reduced mutp53 levels in cells with wtDNAJA1,

whereas it failed to reduce mutp53 in cells expressing mutDNAJA1. We also conﬁrmed that A11 reduced endogenous DNAJB6,
but not DNAJC6, in all subcell lines examined including DNAJA1KO CAL33 cells. Essentially, the same results were obtained using
Cell Death Discovery (2022)8:437
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Fig. 2 Analogue screen identiﬁes A11, showing an increased activity to deplete DNAJA1 and conformational mutp53. A Summary of
relative immunoﬂuorescence intensity for DNAJA1 and p53 using KHOS/NP cells treated with 7-3 and 25 analogues (40 µM, 24 h) and chemical
structure of A11. B Western blotting and immunoﬂuorescence for indicated proteins using KHOS/NP cells treated with DMSO (D), 7-3, or A11
(40 µM, 24 h). Scale bar: 50 µm. C CETSA for DNAJA1 and Vinculin using MG63-p53R175H cells treated with D or A11 (A, 100 µM, 4 h) with a
quantitative graph. Mean ± SEM (n = 4). *p < 0.05; two-way ANOVA. D Western blotting for indicated proteins using KHOS/NP (p53R156P), H2087
(p53V157F), CAL33 (p53R175H), and Huh7 (p53Y220C) cells treated with D or A (20 µM, 24 h). E, F Western blotting and immunoﬂuorescence for
indicated proteins, using MDA-MB-231 (p53R280K), HCT116 (p53+/+), and H1299 (p53null) cells (E), as well as MG63-p53R175H and MG63-p53R273H
cells (F), treated with A11 (20 µM, 24 h). Scale bar: 50 µm. G, H Western blotting or immunoﬂuorescence for indicated proteins using KHOS/NP
cells treated with different concentrations of D or A11 for 24 h (G) and at 20 µM of D or A11 for 12–48 h (H). Scale bar: 50 µm.

Fig. 3 A11 induces proteasomal degradation of DNAJA1 and subsequently reduces conformational mutp53. A Western blotting for
indicated proteins using CAL33 cells treated with A11 at 20 µM for 12–24 h with a quantitative graph. Mean ± SEM (n = 3). B Western blotting
for indicated proteins using control and DNAJA1-KO CAL33 cells treated with DMSO (D) or A11 (A, 20 µM, 24 h). C CETSA for p53 and Vinculin
with DNAJA1-KO CAL33 cells treated with D or A (100 µM, 4 h) with a quantitative graph. Mean ± SEM (n = 3). n.s. not signiﬁcant; two-way
ANOVA. D Western blotting for indicated proteins using CAL33 cells treated with A11 at 40 µM with or without cycloheximide (CHX, 100 ng/
mL) for different treatment periods with a quantitative graph. Mean ± SEM (n = 3). *p < 0.05; two-way ANOVA. E Western blotting for DNAJA1
and GAPDH using CAL33 cells treated with D or A (20 µM, 12 h) and additional D or A treatments with or without MG-132 (30 µM, 8 h).

DNAJA1-KO KHOS/NP cells re-introduced for wtDNAJA1 or
mutDNAJA1 (Supplementary Fig. 6A, B).
Next, we examined the effects of A11 on ﬁlopodia formation
and migration using these CAL33 and KHOS/NP subcell lines
(Fig. 6C, D). Both wtDNAJA1 and mutDNAJA1 rescued the
ﬁlopodia-forming and migratory potential of DNAJA1-KO CAL33
and KHOS/NP cells, respectively. A11 reduced ﬁlopodia formation
and migration in cells expressing either endogenous (control) or
exogenous wtDNAJA1; however, DNAJA1-KO cells and those
expressing mutDNAJA1 failed to respond to A11. Furthermore, we
conﬁrmed that A11 bound to exogenously expressed wtDNAJA1,
but not mutDNAJA1, in DNAJA1-KO CAL33 cells by CETSA (Fig. 6E).
Together, these results indicate that binding of A11 to DNAJA1
Cell Death Discovery (2022)8:437

through Y7, K44, and Q47 is crucial for triggering degradation of
DNAJA1 and subsequent depletion of conformational mutp53,
leading to inhibition of ﬁlopodia formation and migration.
DISCUSSION
This is the ﬁrst study identifying an uncharacterized DNAJA1
inhibitor through a virtual screen of ~10 million compounds for
the J-domain of DNAJA1 using a protocol designed by Johnson
et al [30, 31]. We identify “A11” that depletes DNAJA1 and
subsequently conformational mutp53. A11 inhibits cancer cell
migration in a manner dependent on DNAJA1 and conformational
mutp53, showing the on-target effect. A11’s activity appears to be
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Fig. 4 A11 inhibits migratory potential in a manner dependent on DNAJA1 and conformational mutp53. A Summary of 72h-IC50 values of
A11 in multiple human cancer and non-tumor cell lines. 72h-IC50s (µM) for cancer cells with conformational mutp53 (conf.): CAL33 (black,
13.8 µM), Huh7 (red, 20.7), KHOS/NP (blue, 16.6); DNA-contact mutp53 (contact): HSC4 (black, 53.7), FaDu (red, 84.8), MDA-MB-231 (blue, 111.4);
wild-type p53 (wt): U2OS (black, 80.7), SJSA1 (red, 57.7), HCT116 p53+/+ (blue, 78.6); p53 null (null): H1299 (black, 57.9), MG63 (red, 72.6),
HCT116 p53−/− (blue, 58.7). Non-tumor cells (wtp53): HOE (black, 136.1), WI-38 (red, 243.4), BJ (blue, 414.9). *p < 0.05; two-tailed Student’s t-test
(n = 3). B MTT assays (Mean ± SEM, n = 8), using control, DNAJA1-knockout (JA1-KO), and p53-knockout (p53-KO) KHOS/NP cells. C Summary
and images of transwell migration assays using control, DNAJA1-KO, or p53-KO KHOS/NP cells treated with DMSO (D) or A11 (A, 20 µM, 12 h).
Cells were pre-treated with A11 for 12 h. *p < 0.05; two-tailed Student’s t-test (n = 3). n.s. not signiﬁcant. Scale bar: 100 µm. D Summary and
images of F-actin staining using indicated KHOS/NP subcell lines treated with A11 (20 µM, 24 h). *p < 0.05; two-tailed Student’s t-test (n = 3).
n.s. not signiﬁcant. Scale bar: 50 µm. E Blots and summary of Rac1/Cdc42 activation assays using KHOS/NP cells treated with D or A (20 µM,
18 h). Mean ± SEM (n = 3). *p < 0.05; two-tailed Student’s t-test.
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Fig. 5 A11 decreases protein levels of other HSP40/JDP members. A, B Western blotting (A) and immunoﬂuorescence (B) for indicated
proteins, using KHOS/NP cells treated with DMSO (D) or A11 (A, 20 µM, 24 h). Scale bar: 50 µm. C CETSA for DNAJB6, DNAJC6, and Vinculin,
using MG63-p53R175H cells treated with D or A. A quantitative graph (lower). Mean ± SEM (n = 3). *p < 0.05; two-way ANOVA. n.s. not
signiﬁcant. D Amino acid sequence alignment of J-domains of HSP40/JDPs, with information of positions at Y7, K44, Q47 (green) and response
to A11 (Good: ++, some response: +, little or no: +/−).
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Fig. 6 A triple mutant DNAJA1 does not respond to A11. A, B Western blotting (A) and immunoﬂuorescence (B) for indicated proteins, using
control and JA1-KO CAL33 cells with or without wtDNAJA1 (wt) or triple mutDNAJA1 (mut), treated with DMSO (D) or A11 (A, 20 µM, 24 h).
Scale bar: 50 µm. C Summary and images of F-actin staining using CAL33 subcell lines treated with D or A (20 µM, 24 h). Scale bar: 50 µm.
Mean ± SEM (n = 3). *p < 0.05; two-tailed Student’s t-test. n.s. not signiﬁcant. D Summary and images of transwell migration assays,
using KHOS/NP subcell lines treated with D or A (20 µM, 12 h). Cells were pre-treated with D or A for 12 h. Mean ± SEM (n = 3). *p < 0.05; twotailed Student’s t-test. n.s. not signiﬁcant. Scale bar: 100 µm. E CETSA for wtDNAJA1, mutDNAJA1, and Vinculin, using wtDNAJA1 or
mutDNAJA1-expressing JA1-KO CAL33 cells treated with D or A, with quantitative graphs. Mean ± SEM (n = 4). *p < 0.05; two-way ANOVA. n.s.
not signiﬁcant.

dependent on Y7, K44, and Q47 in J-domain. Indeed, A11 binds to
and reduces protein levels of other HSP40/JDPs containing these
three amino acids. Since each HSP40/JDP likely has different client
proteins, this could explain the DNAJA1- or conformational
mutp53-independent anti-proliferative activity of A11.

Moses et al. [32] previously identiﬁed chalcone C86 that induces
degradation of androgen receptor (AR) and its variant ARv. C86
binds to several members of HSP40/JDPs, including DNAJA1;
however, the effects of C86 on mutp53 are not investigated. It is
also unclear whether biological effects of C86 are dependent on
Cell Death Discovery (2022)8:437
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C86-binding HSP40/JDPs, since cells lacking HSP40/JDPs are not
used. Tong et al. [33] recently identiﬁed a compound, GY1-22, that
interacted with interface of the interacting pocket of DNAJA1 and
p53R175H (mouse p53R172H), leading to depletion of p53R175H. GY122 inhibits binding between DNAJA1 and p53R175H in cells, which
depletes p53R175H and cyclin D1 with increased p21 levels for
unclear reasons and inhibits in vivo tumor growth of p53R172Hexpressing murine pancreatic carcinoma cells [33]. This study also
does not address whether biological phenotypes induced by GY122 are dependent on DNAJA1 or p53R175H and if GY1-22 could
deplete other p53 mutants than p53R175H. Notably, neither C86
nor GY1-22 alters protein levels of DNAJA1, unlike A11. Thus, the
mechanism of action of A11 is unique and distinct.
DNAJA1 is also shown to interact with other proteins than
mutp53, as a molecular chaperone. DNAJA1 enhances formation
of aggregation of polyQ74htt in the Huntington’s disease model
[34, 35], reduces aggregation of neurodegenerative disorderassociated tau [36], and promotes folding of newly synthesized
cystic ﬁbrosis transmembrane conductance regulator at the
endoplasmic reticulum [37–39]. DNAJA1 also stabilizes cell
division cycle 45 to promote tumor progression [40], while it
binds to transglutaminase 2 associated with cell survival [41].
Thus, A11 could have an impact on these diverse cellular
activities and their related disease progression. Future pre-clinical
studies, including structural activity relationship to improve
efﬁcacy and speciﬁcity, as well as the pharmacological and
toxicological characterization, are required to identify clinically
applicable HSP40/JDP inhibitors.
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